Skip to content

Clozapine

SGA • Last reviewed 2025-09-23

Brands: Clozaril

Sources updated 2025 • 1 references

Summary

General Information

Indicated for: Treatment-resistant schizophrenia; reduction in risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder. Second‑generation antipsychotic (SGA)

Dosage & Administration

Typical dose range: 300–600 mg/day (target), up to 900 mg/day

Therapeutic level: 350–600 ng/mL

Indications (label)

Treatment-resistant schizophrenia; reduction in risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder.

View labelExact

Mechanism (brief)

Low D2 affinity; higher D4; serotonergic, adrenergic, histaminergic, and anticholinergic activity.

Metabolism & Half‑life

  • Metabolism: Primarily CYP1A2 (also 3A4, 2D6). Smoking induces clearance.
  • Half‑life: ~12 h (steady state ~12–16 h).

Therapeutic Drug Monitoring (TDM)

Recommended: Yes

Reference range: 350–600 ng/mL

Sampling: 12‑h trough (or pre‑AM dose)

Source: AGNP 2018; label

References